Market Overview:
The global immunosuppressive agents market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to factors such as rising incidence of organ transplantations, increasing prevalence of cancer, and technological advancements in the field of immunosuppressive drugs. However, the high cost associated with these drugs is likely to restrain the growth of this market during the forecast period. The global immunosuppressive agents market can be segmented on the basis of type into cyclosporin, tacrolimus, everolimus, sirolimus, and mycophenolic acid. The tacrolimus segment is expected to account for a major share of this market during the forecast period owing to its high demand for use in organ transplantation surgeries. On the basis on application, this market can be divided into innate immune disease treatment (such as psoriasis), organ transplant (such as kidney transplants), cancer treatment (such as leukemia), and other applications (including autoimmune diseases).
Product Definition:
Immunosuppressive agents are drugs that suppress the immune system. They are used to prevent organ rejection in transplant patients and to treat autoimmune diseases such as rheumatoid arthritis and lupus. Immunosuppressive agents can also be used to treat cancer, psoriasis, and other conditions.
Cyclosporin:
Cyclosporin is an immunosuppressive drug that interferes with the body's natural immune response. It was first produced as a cyclic peptide antibiotic and has been used in humans for more than 20 years. The drug has found its usage in the treatment of rheumatoid arthritis, psoriasis, Crohn’s disease and cancer (as a palliative).
Tacrolimus:
Tacrolimus is an immunosuppressive drug that works by decreasing the immune response to any foreign substance, including drugs and bacteria. It does not affect the body's ability to fight off infections or diseases; rather it lowers the inflammatory response caused by certain immune system components. This drug decreases T-cell dependent immunity in humans as well as mice.
Application Insights:
Innate immune disease treatment segment dominated the global immunosuppressive agents market in 2017. This is due to a rise in autoimmune diseases, such as rheumatoid arthritis, lupus, scleroderma and diabetes. Moreover, an increase in organ transplantation procedures also contributes to the growth of this segment. According to data published by the United Nations Office on Drugs and Crime (UNODC), around 120 million people globally are living with a chronic illness or disability caused by an auto-immune disease or by malnutrition due to lack of food intake. Thus, increasing incidences of these disorders will boost demand for immunosuppressive drugs during the forecast period.
The cancer treatment segment is expected register significant growth over the forecast period owing to rising prevalence rates globally for different types of cancers coupled with increasing government funding towards cancer research.
Regional Analysis:
North America dominated the global immunosuppressive agents market in 2017. The presence of a large number of biotechnology and pharmaceutical companies, advanced healthcare infrastructure, high R&D investment by the companies and government support for innovation are some factors responsible for its dominance. In addition, increasing cases of organ transplantation in this region is also expected to drive growth during the forecast period. For instance, as per data published by U.
Asia Pacific is anticipated to be one of the fastest-growing regions over the forecast period owing to rising disposable income coupled with growing awareness regarding treatment options available in emerging countries such as China & India along with Japan.
Growth Factors:
- Increasing incidence of autoimmune diseases: The global incidence of autoimmune diseases is increasing at a significant rate. This is primarily attributed to the changing lifestyle and environmental factors. Immunosuppressive agents are used to treat various autoimmune diseases, which is expected to drive the market growth.
- Growing demand for organ transplants: There is a growing demand for organ transplants due to the increasing prevalence of organ failures and rising awareness about transplant surgeries among people. Immunosuppressive agents are used as part of the post-transplant therapy, which is expected to fuel market growth during the forecast period.
- Technological advancements in immunosuppressive therapies: The technological advancements in immunosuppressive therapies have led to the development of novel drugs with better efficacy and safety profiles than traditional therapies. This is likely to boost market growth during the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Immunosuppressive Agents Market Research Report
By Type
Cyclosporin, Tacrolimus, Everolimus, Sirolimus, Mycophenolic Acid
By Application
Innate Immune Disease Treatment, Organ Transplant, Cancer Treatment, Other
By Companies
Huadong Medicine, Fujisawa Pharmaceutical Co Ltd, Astellas, Roche, Novartis, North China Pharmaceutical Group
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
138
Number of Tables & Figures
97
Customization Available
Yes, the report can be customized as per your need.
Global Immunosuppressive Agents Market Report Segments:
The global Immunosuppressive Agents market is segmented on the basis of:
Types
Cyclosporin, Tacrolimus, Everolimus, Sirolimus, Mycophenolic Acid
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Innate Immune Disease Treatment, Organ Transplant, Cancer Treatment, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Huadong Medicine
- Fujisawa Pharmaceutical Co Ltd
- Astellas
- Roche
- Novartis
- North China Pharmaceutical Group
Highlights of The Immunosuppressive Agents Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Cyclosporin
- Tacrolimus
- Everolimus
- Sirolimus
- Mycophenolic Acid
- By Application:
- Innate Immune Disease Treatment
- Organ Transplant
- Cancer Treatment
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Immunosuppressive Agents Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Immunosuppressive agents are medications that suppress the immune system. This can be done by blocking certain proteins or cells in the immune system, or by stopping the body from making antibodies. Immunosuppressive agents are used to treat a variety of conditions, including cancer, autoimmune diseases (such as lupus), and organ transplant rejection.
Some of the major companies in the immunosuppressive agents market are Huadong Medicine, Fujisawa Pharmaceutical Co Ltd, Astellas, Roche, Novartis, North China Pharmaceutical Group.
The immunosuppressive agents market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Immunosuppressive Agents Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Immunosuppressive Agents Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Immunosuppressive Agents Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Immunosuppressive Agents Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Immunosuppressive Agents Market Size & Forecast, 2020-2028
4.5.1 Immunosuppressive Agents Market Size and Y-o-Y Growth
4.5.2 Immunosuppressive Agents Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Cyclosporin
5.2.2 Tacrolimus
5.2.3 Everolimus
5.2.4 Sirolimus
5.2.5 Mycophenolic Acid
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Innate Immune Disease Treatment
6.2.2 Organ Transplant
6.2.3 Cancer Treatment
6.2.4 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Immunosuppressive Agents Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Immunosuppressive Agents Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Cyclosporin
9.6.2 Tacrolimus
9.6.3 Everolimus
9.6.4 Sirolimus
9.6.5 Mycophenolic Acid
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Innate Immune Disease Treatment
9.10.2 Organ Transplant
9.10.3 Cancer Treatment
9.10.4 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Cyclosporin
10.6.2 Tacrolimus
10.6.3 Everolimus
10.6.4 Sirolimus
10.6.5 Mycophenolic Acid
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Innate Immune Disease Treatment
10.10.2 Organ Transplant
10.10.3 Cancer Treatment
10.10.4 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Cyclosporin
11.6.2 Tacrolimus
11.6.3 Everolimus
11.6.4 Sirolimus
11.6.5 Mycophenolic Acid
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Innate Immune Disease Treatment
11.10.2 Organ Transplant
11.10.3 Cancer Treatment
11.10.4 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Cyclosporin
12.6.2 Tacrolimus
12.6.3 Everolimus
12.6.4 Sirolimus
12.6.5 Mycophenolic Acid
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Innate Immune Disease Treatment
12.10.2 Organ Transplant
12.10.3 Cancer Treatment
12.10.4 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Cyclosporin
13.6.2 Tacrolimus
13.6.3 Everolimus
13.6.4 Sirolimus
13.6.5 Mycophenolic Acid
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Innate Immune Disease Treatment
13.10.2 Organ Transplant
13.10.3 Cancer Treatment
13.10.4 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Immunosuppressive Agents Market: Competitive Dashboard
14.2 Global Immunosuppressive Agents Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Huadong Medicine
14.3.2 Fujisawa Pharmaceutical Co Ltd
14.3.3 Astellas
14.3.4 Roche
14.3.5 Novartis
14.3.6 North China Pharmaceutical Group
